EDITORIAL: Lilly looks forward with ImClone deal: CEO Lechleiter taking bold steps
Lilly looks forward with ImClone deal CEO Lechleiter taking bold steps It’s premature to pass judgment on Eli Lilly and Co.’s $6.5 billion plan to acquire biotech firm ImClone Systems Inc., but the giant deal is one more sign that relatively new CEO John Lechleiter isn’t afraid to make bold moves on Lilly’s behalf. The local drugmaker agreed Oct. 6 to pay $70 a share for New York-based ImClone, maker of blockbuster cancer drug Erbitux, outbidding an earlier offer of…